This year InSysBio celebrates its 20-year anniversary. During this period the company made the way from modeling in systems biology and biotechnology to pharmacometrics modeling services. Now InSysBio specializes in Quantitative Systems Pharmacology (QSP) modeling services and QSP software infrastructure development and operates in the global market.
InSysBio was founded in 2004 and since then has evolved into a group of companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). Part of InSysBio team relocated to Limassol, Cyprus after the start of operation of new Headquarters there, thus, expanding the company’s presence.
InSysBio has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. This experience covers a wide range of therapeutic areas: inflammatory disease, autoimmune disease, diabetes and obesity, cardiovascular diseases, infectious diseases, metabolic diseases, diseases associated with kidney dysfunction, pain and rare diseases. Currently InSysBio mainly focuses on QSP models and platforms in immunology, oncology and immuno-oncology and neurodegenerative diseases.
InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The focus of projects went through a range of transformations on the way to QSP modeling services. Over the years of operation InSysBio carried out modeling in systems biology, then modeling of biotechnological processes and drug safety. Now InSysBio develops models of such types as mechanistic PK/PD, PK/RO, PBPK/RO, QSP fit for purpose, QSP platforms. The modality of services includes small molecule, mAb, bispecific and multispecific Ab, T cell engagers, Antibody Drug Conjugate, cell therapy, gene therapy.
Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, comments on InSysBio’s approach, “Over the past 20 years the perception of QSP has changed and the changes are still underway. For instance, a simple-minded view on QSP as a universal tool able to address a range of the issues of drug research and development is evolving into a pragmatic view on QSP as an approach to meet quite particular challenges. Our company is developing according to this evolvement. I hope at least part of these changes in the perception of QSP has occurred due to InSysBio’s proactive and consistent position. I suppose this will continue”.
In 2015 InSysBio started development of its QSP software infrastructure for external and internal usage. Since then, the infrastructure is being constantly updated and extended. The range of InSysBio’s tools and databases embraces Immune Response Template (IRT), Heta compiler, HetaSimulator.jl, CYTOCON DB, fIVE DB, DBSolveOptimum, SbmlViewer, LikelihoodProfiler. The implementation of QSP tools allows to simplify modeling process.
InSysBio continues the development of its QSP services and tools according to its mission, vision and values, namely, providing QSP modeling to world pharma, contributing our expertise to global QSP community and creating favorable atmosphere for self-development of researchers. Every year InSysBio team publishes their articles in scientific journals and presents at the most valuable industry conferences, namely, ACoP, SITC, PAGE, ASCPT, AAIC, QSPC etc. There are more than 150 papers and posters presented by InSysBio team now.
Moreover, InSysBio provides consultancy services and educational assistance to academic entities. Besides, InSysBio develops blog which core idea is to provide a unique collection of methodological materials on QSP modeling that has no analogue. The company’s diverse expertise and corporate philosophy were carefully reflected through rebranding twice at different stages if InSysBio’s development.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Jun 2020 13:24
InSysBio to announce the launch of QSP model of COVID-19
The new open source project to be developed and updated Online
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
3
|
4
|
5
1.
05 Jun 2020 15:04
InSysBio to present IRT Navigator 3
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
|
6
|
7
|
|
8
1.
08 Jun 2020 15:30
InSysBio to perform the first step in development of COVID-19 QSP model
InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
9
|
10
|
11
|
12
1.
12 Jun 2020 16:45
InSysBio to release the new version of Cytocon DB 1.1.6.4
We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
|
13
|
14
|
|
15
|
16
|
17
1.
17 Jun 2020 15:48
InSysBio to welcome its new team member Dr. Neil Benson
InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development
(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
|
18
|
19
|
20
|
21
|
|
22
1.
22 Jun 2020 17:04
InSysBio team posters to be presented at AACR Virtual Annual Meeting II
AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
1.
30 Jun 2020 15:45
InSysBio to present COVID-19 QSP model further development
InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
| |||||
Thank you for your message! We will get back to you shortly.
